INHIBIKASE THERAPEUTICS INC (IKT) Stock Cash Flow
NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -19.57M | -19.03M | -18.05M | -14.79M | -2.85M | |||
| Depreciation Amortization | 27.11K | 177.40K | 10.00K | N/A | N/A | |||
| Change In Working Capital | 1.93M | 234.76K | 170.00K | -1.76M | -460.00K | |||
| Interest Paid | N/A | 0.00 | 0.00 | 0.00 | 10.00K | |||
| Other non cash items | 363.84K | 531.68K | 530.00K | 2.25M | 2.18M | |||
| OPERATING CASH FLOW | -17.25M | -18.09M | -17.35M | -14.30M | -1.13M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | N/A | -14.24K | -240.00K | N/A | N/A | |||
| Other Investing Activity | -361.58K | 11.67M | -15.76M | N/A | N/A | |||
| INVESTING CASH FLOW | -355.81K | 11.66M | -16.01M | N/A | N/A | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | N/A | 0.00 | -250.00K | -40.00K | 270.00K | |||
| Stock Issued/Repurchased | 3.80M | 8.54M | 40.00K | 41.21M | 14.79M | |||
| Other Financing Activity | N/A | -138.56K | 0.00 | -80.00K | N/A | |||
| FINANCING CASH FLOW | 3.66M | 8.40M | -200.00K | 41.09M | 15.06M | |||
| CHANGE IN CASH | -13.95M | 1.98M | -33.56M | 26.80M | 13.94M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -17.25M | -18.09M | -17.35M | -14.30M | -1.13M | |||
| Capital Expenditure | N/A | -14.24K | -240.00K | N/A | N/A | |||
| FREE CASH FLOW | -17.25M | -18.10M | -17.59M | -14.30M | -1.13M | |||
All data in USD